$SILK
Silk Road Medical Inc Stock $silk

$silk Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-K Financial Statement

#000139770222000012 Filed on March 01, 2022

Income Statement

Concept	2022 Q1	2021 Q4	2021
Revenue	$28.02M	$28.27M	$101.5M
YoY Change	27.06%	33.75%	34.89%
Cost Of Revenue	$8.577M	$7.233M	$25.45M
YoY Change	54.88%	38.56%	19.52%
Gross Profit	$19.44M	$21.03M	$76.03M
YoY Change	17.74%	32.14%	40.96%
Gross Profit Margin	69.39%	74.41%	74.92%
Selling, General & Admin	$27.28M	$27.60M	$96.39M
YoY Change	28.69%	32.22%	27.62%
% of Gross Profit	140.27%	131.2%	126.78%
Research & Development	$8.123M	$7.499M	$27.11M
YoY Change	48.12%	-25.31%	27.45%
% of Gross Profit	41.78%	35.66%	35.66%
Depreciation & Amortization	$420.0K	$309.0K	$1.032M
YoY Change	75.0%	34.35%	30.8%
% of Gross Profit	2.16%	1.47%	1.36%
Operating Expenses	$35.40M	$35.09M	$123.5M
YoY Change	32.69%	13.54%	27.59%
Operating Profit	-$15.95M	-$14.06M	-$47.47M
YoY Change	56.98%	-6.22%	10.75%
Interest Expense	$621.0K	-$619.0K	$2.518M
YoY Change	-0.32%	-3.28%	-42.92%
% of Operating Profit
Other Income/Expense, Net	-$116.0K	-$12.00K	-$23.00K
YoY Change	3766.67%	20.0%	-71.25%
Pretax Income	-$16.68M	-$14.69M	-$49.81M
YoY Change	56.02%	-12.33%	5.16%
Income Tax			$20.00K
% Of Pretax Income
Net Earnings	-$16.68M	-$14.69M	-$49.81M
YoY Change	55.97%	-12.31%	5.16%
Net Earnings / Revenue	-59.52%	-51.98%	-49.09%
Basic Earnings Per Share	-$0.48		-$1.44
Diluted Earnings Per Share	-$476.2K	-$420.6K	-$1.438M
COMMON SHARES
Basic Shares Outstanding	35.01M	34.90M	34.64M
Diluted Shares Outstanding	35.02M		34.64M

Balance Sheet

Concept	2022 Q1	2021 Q4	2021
SHORT-TERM ASSETS
Cash & Short-Term Investments	$93.60M	$110.2M	$110.2M
YoY Change	-31.23%	-25.26%	-25.27%
Cash & Equivalents	$93.60M	$110.2M	$110.2M
Short-Term Investments		$0.00	$0.00
Other Short-Term Assets	$2.564M	$3.412M	$3.412M
YoY Change	-46.58%	-49.82%	-49.82%
Inventory	$17.73M	$17.85M	$17.85M
Prepaid Expenses
Receivables	$13.88M	$11.83M	$11.83M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$127.8M	$143.3M	$143.3M
YoY Change	-22.04%	-17.31%	-17.3%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.866M	$7.697M	$12.92M
YoY Change	255.28%	170.64%	130.64%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$5.134M	$5.370M	$383.0K
YoY Change	91.57%	89.62%	27.67%
Total Long-Term Assets	$15.23M	$13.30M	$13.30M
YoY Change	164.12%	122.17%	121.65%
TOTAL ASSETS
Total Short-Term Assets	$127.8M	$143.3M	$143.3M
Total Long-Term Assets	$15.23M	$13.30M	$13.30M
Total Assets	$143.0M	$156.6M	$156.6M
YoY Change	-15.71%	-12.65%	-12.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.926M	$2.379M	$2.379M
YoY Change	0.1%	-8.43%	-8.5%
Accrued Expenses	$16.74M	$19.80M	$19.65M
YoY Change	25.98%	16.78%	16.93%
Deferred Revenue	$522.0K	$157.0K
YoY Change	-2.61%	-23.79%
Short-Term Debt	$9.829M	$3.905M	$3.905M
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$29.50M	$26.09M	$26.09M
YoY Change	81.94%	33.4%	33.09%
LONG-TERM LIABILITIES
Long-Term Debt	$38.90M	$44.79M	$44.79M
YoY Change	-19.91%	-7.72%	-7.66%
Other Long-Term Liabilities	$6.893M	$6.513M	$6.513M
YoY Change	85.3%	74.8%	76.03%
Total Long-Term Liabilities	$45.79M	$51.30M	$51.30M
YoY Change	-12.43%	-1.84%	-1.73%
TOTAL LIABILITIES
Total Short-Term Liabilities	$29.50M	$26.09M	$26.09M
Total Long-Term Liabilities	$45.79M	$51.30M	$51.30M
Total Liabilities	$75.29M	$77.39M	$77.39M
YoY Change	9.9%	7.76%	7.78%
SHAREHOLDERS EQUITY
Retained Earnings	-$305.4M	-$288.7M
YoY Change	22.36%	20.85%
Common Stock	$35.00K	$35.00K
YoY Change	2.94%	2.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$67.71M	$79.24M	$79.24M
YoY Change
Total Liabilities & Shareholders Equity	$143.0M	$156.6M	$156.6M
YoY Change	-15.71%	-12.65%	-12.65%

Cashflow Statement

Concept	2022 Q1	2021 Q4	2021
OPERATING ACTIVITIES
Net Income	-$16.68M	-$14.69M	-$49.81M
YoY Change	55.97%	-12.31%	5.16%
Depreciation, Depletion And Amortization	$420.0K	$309.0K	$1.032M
YoY Change	75.0%	34.35%	30.8%
Cash From Operating Activities	-$14.73M	-$11.43M	-$38.94M
YoY Change	23.0%	-19.89%	-7.45%
INVESTING ACTIVITIES
Capital Expenditures	$2.072M	-$2.752M	$4.758M
YoY Change	2992.54%	1000.8%	465.08%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$17.00M	$77.40M
YoY Change	-100.0%	29.29%	-1005.29%
Cash From Investing Activities	-$2.072M	$14.25M	$72.64M
YoY Change	-105.72%	10.47%	-873.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$168.0K		$6.946M
YoY Change	-80.19%		34.4%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	168.0K	1.771M	6.978M
YoY Change	-80.19%	-78.84%	-91.46%
NET CHANGE
Cash From Operating Activities	-14.73M	-11.43M	-38.94M
Cash From Investing Activities	-2.072M	14.25M	72.64M
Cash From Financing Activities	168.0K	1.771M	6.978M
Net Change In Cash	-16.63M	4.589M	40.69M
YoY Change	-166.23%	-34.44%	34.35%
FREE CASH FLOW
Cash From Operating Activities	-$14.73M	-$11.43M	-$38.94M
Capital Expenditures	$2.072M	-$2.752M	$4.758M
Free Cash Flow	-$16.80M	-$8.680M	-$43.69M
YoY Change	39.52%	-38.09%	1.82%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	47861000
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001397702
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-38847
CY2021	dei	Entity Registrant Name EntityRegistrantName	SILK ROAD MEDICAL, INC.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-8777622
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	1213 Innsbruck Dr.
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Sunnyvale
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94089
CY2021	dei	City Area Code CityAreaCode	408
CY2021	dei	Local Phone Number LocalPhoneNumber	720-9002
CY2021	dei	Security12b Title Security12bTitle	Common Stock
CY2021	dei	Trading Symbol TradingSymbol	SILK
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	1600000000
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	35010136
CY2021	dei	Auditor Firm AuditorFirmId	238
CY2021	dei	Auditor Name AuditorName	PricewaterhouseCoopers LLP
CY2021	dei	Auditor Location AuditorLocation	San Jose, California
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	110231000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	69466000
CY2020Q4	us-gaap	Short Term Investments ShortTermInvestments	78016000
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	6000
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	13000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	11832000
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9070000
CY2021Q4	us-gaap	Inventory Net InventoryNet	17851000
CY2020Q4	us-gaap	Inventory Net InventoryNet	9989000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3412000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6787000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	143326000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	173328000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7697000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2844000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	232000
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	310000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5370000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2832000
CY2021Q4	us-gaap	Assets Assets	156625000
CY2020Q4	us-gaap	Assets Assets	179314000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2379000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2598000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	19802000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	16957000
CY2021Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	3905000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	26086000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19555000
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	44786000
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	48533000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6513000
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3726000
CY2021Q4	us-gaap	Liabilities Liabilities	77385000
CY2020Q4	us-gaap	Liabilities Liabilities	71814000
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34980896
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34980896
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34249649
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34249649
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	35000
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	34000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	367907000
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	346318000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	39000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-288702000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-238891000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	79240000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	107500000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	156625000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	179314000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	101475000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	75227000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	63354000
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	25446000
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	21291000
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	15927000
CY2021	us-gaap	Gross Profit GrossProfit	76029000
CY2020	us-gaap	Gross Profit GrossProfit	53936000
CY2019	us-gaap	Gross Profit GrossProfit	47427000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27110000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21271000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12272000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	96387000
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	75524000
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	63220000
CY2021	us-gaap	Operating Expenses OperatingExpenses	123497000
CY2020	us-gaap	Operating Expenses OperatingExpenses	96795000
CY2019	us-gaap	Operating Expenses OperatingExpenses	75492000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-47468000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-42859000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-28065000
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	198000
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	1104000
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	1656000
CY2021	us-gaap	Interest Expense InterestExpense	2518000
CY2020	us-gaap	Interest Expense InterestExpense	4411000
CY2019	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent	2000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-39000
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	37000
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	2000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-49850000
CY2019	us-gaap	Interest Expense InterestExpense	4952000
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1119000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-23000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-80000
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-21054000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-49811000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-47365000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-52415000
CY2021	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent	-39000
CY2020	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent	37000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-47328000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-52413000
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.44
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.44
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.28
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	34635358
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	32965539
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	22956679
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-134553000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	31000
CY2019	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	10961000
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	109119000
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1542000
CY2019	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1048000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	2977000
CY2019	us-gaap	Profit Loss ProfitLoss	-52415000
CY2019	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax	2000
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	71891000
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4457000
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	70543000
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3487000
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1681000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	7226000
CY2020	us-gaap	Profit Loss ProfitLoss	-47365000
CY2020	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax	37000
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	107500000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4842000
CY2019	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	21030000
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-577000
CY2020	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-304000
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2104000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	14612000
CY2021	silk	Disgorgement Of Stockholder S Short Swing Profits DisgorgementOfStockholderSShortSwingProfits	32000
CY2021	us-gaap	Profit Loss ProfitLoss	-49811000
CY2021	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax	-39000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	79240000
CY2021	us-gaap	Profit Loss ProfitLoss	-49811000
CY2020	us-gaap	Profit Loss ProfitLoss	-47365000
CY2019	us-gaap	Profit Loss ProfitLoss	-52415000
CY2021	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	1032000
CY2020	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	789000
CY2019	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	712000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	14612000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	7226000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	2977000
CY2019	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	309000
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	158000
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	66000
CY2019	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	46000
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	887000
CY2020	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	602000
CY2019	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	582000
CY2020	us-gaap	Paid In Kind Interest PaidInKindInterest	241000
CY2019	us-gaap	Paid In Kind Interest PaidInKindInterest	672000
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1119000
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-9000
CY2020	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-52000
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	6000
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-32000
CY2019	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	23000
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	77000
CY2020	us-gaap	Inventory Write Down InventoryWriteDown	117000
CY2019	us-gaap	Inventory Write Down InventoryWriteDown	118000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2769000
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	437000
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2241000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5563000
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2161000
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4696000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	772000
CY2019Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	20.00
CY2020	silk	Stock Issuance Costs Incurred But Not Yet Paid StockIssuanceCostsIncurredButNotYetPaid	25000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3307000
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	108000
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	32000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	30285000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	14191000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	69776000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	39491000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25300000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	110463000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	69776000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	39491000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	2360000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	7917000
CY2019	us-gaap	Interest Paid Net InterestPaidNet	4234000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1138000
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3982000
CY2019	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	37121000
CY2019	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	144140000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-288702000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	110231000
CY2019Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	2.7
CY2019Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	6000000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-250000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1471000
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	117000
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-210000
CY2019	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-552000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1159000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	592000
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	615000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	4418000
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	146000
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	4964000
CY2021	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-520000
CY2020	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	26000
CY2019	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-769000
CY2020	silk	Repayment Of Paid In Kind Interest RepaymentOfPaidInKindInterest	3813000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-38935000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-42068000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-29610000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4758000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	842000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	535000
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	2000
CY2020	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	79906000
CY2019	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	69421000
CY2021	us-gaap	Proceeds From Maturities Prepayments And Calls Of Other Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments	77400000
CY2020	us-gaap	Proceeds From Maturities Prepayments And Calls Of Other Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments	71355000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	72644000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9393000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-69956000
CY2020	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	70568000
CY2019	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	109352000
CY2020	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	48506000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6946000
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5168000
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2590000
CY2020	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	40000000
CY2020	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	2496000
CY2021	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	32000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6978000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	81746000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	113757000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	40687000
CY2019Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	39.50
CY2019Q2	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	109119000
CY2019Q2	silk	Payment Of Stock Issuance Underwriting Discounts And Commissions PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions	8400000
CY2019Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2481000
CY2020Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	6808154
CY2020Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	39.00
CY2020Q2	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	70543000
CY2020Q2	silk	Payment Of Stock Issuance Underwriting Discounts And Commissions PaymentOfStockIssuanceUnderwritingDiscountsAndCommissions	3750000
CY2020Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	707000
CY2021	us-gaap	Use Of Estimates UseOfEstimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses judgment when making estimates related to provisions for accounts receivable and excess and obsolete inventories, the valuation of deferred tax assets, the reserves for sales returns, stock-based compensation, and for periods prior to the Company's IPO, the valuation of common stock and redeemable convertible preferred stock warrants. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately differ from these estimates and assumptions. Due to the coronavirus (“COVID-19”) pandemic, there has been continued uncertainty and disruption in the global economy, supply chain, financial markets and increased labor shortages. While some of the uncertainties began to lift throughout the first half of 2021, new virus variants, and increased infection rates during the second half of 2021 continue to make the current COVID-related environment highly volatile and uncertain. These challenges continued to impact the number of TCAR procedures in 2021, with procedure volumes impacted by increased COVID-19 hospitalizations and hospital capacity constraints due to the COVID-19 and its variants. The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of December 31, 2021. The Company has also considered information available to it as of the date of issuance of these financial statements and is not aware of any specific events or circumstances that would require an update to its estimates or judgments, or a revision to the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information becomes available. Actual results could differ materially from these estimates.
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	110231000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	69466000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	232000
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	310000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	110463000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	69776000
CY2019	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2020	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2021	us-gaap	Advertising Expense AdvertisingExpense	221000
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	Concentration of Credit Risk, and Other Risks and Uncertainties The Company is subject to risks related to public health crises such as the global pandemic associated with COVID-19. The COVID-19 outbreak has negatively impacted, and may continue to negatively impact the Company’s operations, its revenue and overall financial condition by significantly decreasing the number of TCAR procedures performed. The number of TCAR procedures performed, similar to other surgical procedures, has significantly decreased as health care organizations globally prioritized the treatment of patients with COVID-19. In the past governmental authorities have recommended, and in certain cases required, that elective, specialty and other procedures and appointments, be suspended or canceled to focus limited resources and personnel and hospital capacity toward the treatment of COVID-19 and to avoid exposing patients to COVID-19. These measures and challenges will likely continue for the duration of the pandemic, which is uncertain, and will continue to negatively impact the Company’s revenue while the pandemic continues. New virus variants, and increased infection rates continue to make the current COVID-related environment highly volatile and uncertain. Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents, investments and accounts receivable to the extent of the amounts recorded on the balance sheet. Cash, cash equivalents, and investments are deposited in financial institutions which, at times, may be in excess of federally insured limits. Cash equivalents are invested in highly rated money market funds. The Company invests in a variety of financial instruments, such as, but not limited to, commercial paper, corporate bonds/notes, United States Government securities, asset-backed securities and, by policy, limits the amount of credit exposure with any one financial institution or commercial issuer. The Company has not experienced any material losses on its deposits of cash and cash equivalents or investments during the years ended December 31, 2021 and 2020. The Company’s accounts receivable are due from a variety of health care organizations in the United States. At December 31, 2021 and 2020, no customer represented 10% or more of the Company’s accounts receivable. For the years ended December 31, 2021, 2020 and 2019, there were no customers that represented 10% or more of revenue. The Company provides for uncollectible amounts when specific credit problems are identified. In doing so, the Company analyzes historical bad debt trends, customer credit worthiness, current economic trends and changes in customer payment patterns when evaluating the adequacy of the allowance for expected credit losses on customer accounts. The Company manufactures certain of its commercial products in-house. Certain of the Company’s product components and sub-assemblies continue to be manufactured by sole suppliers, the most significant of which is the ENROUTE Transcarotid Stent System, manufactured by Cordis Corporation. Disruption in component or sub-assembly supply from these manufacturers or from in-house production would have a negative impact on the Company’s financial position and results of operations. The Company is subject to certain risks, including that its devices may not be approved or cleared for marketing by governmental authorities or be successfully marketed. There can be no assurance that the Company’s products will achieve widespread adoption in the marketplace, nor can there be any assurance that existing devices or any future devices can be developed or manufactured at an acceptable cost and with appropriate performance characteristics. The Company is also subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, dependence upon government and third-party payers to provide adequate coverage and reimbursement, dependence on key personnel and suppliers, protection of proprietary technology, product liability claims, and compliance with government regulations. Existing or future devices developed by the Company may require approvals or clearances from the FDA or international regulatory agencies. In addition, in order to continue the Company’s operations, compliance with various federal and state laws is required. If the Company were denied or delayed in receiving such approvals or clearances, it may be necessary to adjust operations to align with the Company’s currently approved portfolio. If clearance for the products in the current portfolio were withdrawn by the FDA, this would have a material adverse impact on the Company.
CY2020	us-gaap	Advertising Expense AdvertisingExpense	194000
CY2019	us-gaap	Advertising Expense AdvertisingExpense	362000
CY2021Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	87000
CY2020Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	71000
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1852000
CY2021Q4	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	0
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-49811000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-47365000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-52415000
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	34635358
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	32965539
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	22956679
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.44
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.44
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.28
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4311213000
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4306224000
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4310790000
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2021	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	42000
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	3000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	146311000
CY2020Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2021Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2020Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2021Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	21062000
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	146272000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	146311000
CY2021Q4	silk	Cash And Cash Equivalents Fair Value Disclosure Maturing Within One Year CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear	21062000
CY2020Q4	silk	Cash And Cash Equivalents Fair Value Disclosure Maturing Within One Year CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear	146311000
CY2021Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	21062000
CY2020Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	146311000
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	15497000
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	3000
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	2447000
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1785000
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	15437000
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	10599000
CY2021Q4	us-gaap	Inventory Gross InventoryGross	17884000
CY2020Q4	us-gaap	Inventory Gross InventoryGross	12384000
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	33000
CY2020Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	2395000
CY2021Q4	us-gaap	Inventory Net InventoryNet	17851000
CY2020Q4	us-gaap	Inventory Net InventoryNet	9989000
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	0
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	0
CY2021Q4	silk	Excess And Obsolete Inventory Reserve ExcessAndObsoleteInventoryReserve	1000
CY2020Q4	silk	Excess And Obsolete Inventory Reserve ExcessAndObsoleteInventoryReserve	2377000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2039000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6284000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4694000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3330000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2332000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7697000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2844000
CY2021	us-gaap	Depreciation Depreciation	1032000
CY2020	us-gaap	Depreciation Depreciation	789000
CY2019	us-gaap	Depreciation Depreciation	712000
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	13898000
CY2020Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	9573000
CY2021Q4	silk	Provisions For Sales Returns ProvisionsForSalesReturns	359000
CY2020Q4	silk	Provisions For Sales Returns ProvisionsForSalesReturns	820000
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2520000
CY2021Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	11000
CY2020Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	1696000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1294000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	850000
CY2021Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	687000
CY2020Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	518000
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	157000
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	206000
CY2021Q4	silk	Accrued Travel Expenses Current AccruedTravelExpensesCurrent	590000
CY2020Q4	silk	Accrued Travel Expenses Current AccruedTravelExpensesCurrent	237000
CY2021Q4	silk	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	99000
CY2020Q4	silk	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	113000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	668000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	424000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	19802000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	16957000
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	6257000
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	25749000
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	21457000
CY2021Q4	silk	Long Term Debt Gross Before Accretion Of Closing Fees LongTermDebtGrossBeforeAccretionOfClosingFees	53463000
CY2021Q4	silk	Long Term Debt Unpaid Interest LongTermDebtUnpaidInterest	4463000
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	309000
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	48691000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	1234000
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	870000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	870000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	34000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	769000
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	721000
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0650
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y10M9D
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0650
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y9M29D
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5219000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2798000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1294000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	850000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5747000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2850000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	7041000
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3700000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	620000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1967000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1764000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	882000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	904000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	2769000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	8906000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1865000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	7041000
CY2021Q4	us-gaap	Unrecorded Unconditional Purchase Obligation Balance Sheet Amount UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount	5661000
CY2020Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0
CY2021Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34980896
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34980896
CY2021	us-gaap	Dividends Common Stock DividendsCommonStock	0
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	7180248
CY2020Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	6660892
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	20.00
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	5968
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0
CY2021	silk	Stockholder Short Swing Profits StockholderShortSwingProfits	32000
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4364377
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.79
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M9D
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	33132000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	848023
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	22.77
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	873786
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.77
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	27824
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	8.71
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4310790
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.91
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M7D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	140234000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1010843
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	40.67
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1018779
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.42
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	65026
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	23.32
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4237828
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	16.56
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M17D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	197407000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	323057
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	53.94
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	643507
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	7.49
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	136439
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	40.30
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3780939
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	20.45
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y8M15D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	91900000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2732674
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	13.64
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y1M17D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	81395000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3780939
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	20.45
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y8M15D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	91900000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	29355000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	24867000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	23.83
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	18.22
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	10.17
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	9076000
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	5138000
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	2221000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3780939
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y8M15D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	20.45
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2732674
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	13.64
CY2021	silk	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairValue	28110000
CY2020	silk	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateFairValue	3186000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14612000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7226000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2977000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-49811000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-47365000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-52415000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-49811000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-47365000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-52415000
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-10460000
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-9947000
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-11007000
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1958000
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-2270000
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	-5224000
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	-8489000
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	-4731000
CY2019	silk	Effective Income Tax Rate Reconciliation Warrant Liability Adjustment Amount EffectiveIncomeTaxRateReconciliationWarrantLiabilityAdjustmentAmount	5330000
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	17918000
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	22164000
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	12797000
CY2021	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	852000
CY2020	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	1268000
CY2019	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	319000
CY2021	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	490000
CY2020	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	-491000
CY2019	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	208000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	20000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	11000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	77616000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	63069000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	7732000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	7191000
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	4000
CY2020Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	8000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	2301000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	2337000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4392000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1859000
CY2021Q4	silk	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	1751000
CY2020Q4	silk	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	935000
CY2021Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	1314000
CY2020Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	813000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	95110000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	76212000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	93207000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	75289000
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	1297000
CY2020Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	707000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1903000
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	606000
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	216000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	923000
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	17918000
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	22163000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3314000
CY2021Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0
CY2019	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2020	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2021	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2019000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1436000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1348000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	704000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	342000
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	88000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	591000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	241000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3314000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2019000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1436000
CY2021	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.90
CY2021	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.50
CY2021	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.05
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1313000
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	959000

Files In Submission

Name	View Source	Status
0001397702-22-000012-index-headers.html	Edgar Link	pending
0001397702-22-000012-index.html	Edgar Link	pending
0001397702-22-000012.txt	Edgar Link	pending
0001397702-22-000012-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
silk-20211231.xsd	Edgar Link	pending
silk-20211231x10k.htm	Edgar Link	pending
silk-20211231x10kg001.jpg	Edgar Link	pending
silk-20211231x10kg002.jpg	Edgar Link	pending
silk-20211231x10kg003.jpg	Edgar Link	pending
silk-20211231x10kg004.jpg	Edgar Link	pending
silk-20211231x10kg005.jpg	Edgar Link	pending
silk-20211231x10k_htm.xml	Edgar Link	completed
silk-20211231xex23_1.htm	Edgar Link	pending
silk-20211231xex31_1.htm	Edgar Link	pending
silk-20211231xex31_2.htm	Edgar Link	pending
silk-20211231xex32_1.htm	Edgar Link	pending
silk-20211231xex4_5.htm	Edgar Link	pending
silk-20211231_cal.xml	Edgar Link	unprocessable
silk-20211231_def.xml	Edgar Link	unprocessable
silk-20211231_lab.xml	Edgar Link	unprocessable
silk-20211231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SILK
Silk Road Medical Inc Stock $silk

2022 Q1 Form 10-K Financial Statement

#000139770222000012 Filed on March 01, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SILK Silk Road Medical Inc Stock $silk

2022 Q1 Form 10-K Financial Statement

#000139770222000012 Filed on March 01, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SILK
Silk Road Medical Inc Stock $silk